Study on molecular evolutionary rules of drug resistance mutations in CRF01-AE subtype of HIV-1 strain by high-throughput sequencing

DENG Yongyue; WU Shouli; QIU Lijun; YAN Yansheng

doi:10.7619/jcmp.20211220

Journal of Clinical Medicine in Practice > 2021 > 25(19): 1-6. > DOI: 10.7619/jcmp.20211220

DENG Yongyue, WU Shouli, QIU Lijun, YAN Yansheng. Study on molecular evolutionary rules of drug resistance mutations in CRF01-AE subtype of HIV-1 strain by high-throughput sequencing[J]. Journal of Clinical Medicine in Practice, 2021, 25(19): 1-6. DOI: 10.7619/jcmp.20211220

Citation:

PDF (721 KB)

Study on molecular evolutionary rules of drug resistance mutations in CRF01-AE subtype of HIV-1 strain by high-throughput sequencing

DENG Yongyue^{1, 2, 3},
WU Shouli^{1, 3},
QIU Lijun⁴,
YAN Yansheng^{1, 3, ,}

1.
School of Public Health, Fujian Medical University, Fuzhou, Fujian, 350001
2.
Department of Infection, Zhongshan Hospital Affiliated to Xiamen University, Xiamen, Fujian, 361000
3.
Fujian Provincial Key Laboratory of Zoonosis Research, Fujian Provincial Center for Disease Control and Prevention, Fuzhou, Fujian, 350001
4.
Department of Infection Management, Fujian Provincial Hospital, Fuzhou, Fujian, 350001

More Information

Received Date: March 21, 2021
Available Online: October 27, 2021
Published Date: October 14, 2021

Graphical Abstract

Abstract

Abstract

Objective To investigate the occurrence and development rules of drug-resistant mutations in CRF01-AE subtype of human immunodeficiency virus type 1 (HIV-1) strain under the pressure of drug selection.
Methods Totally 5 HIV-1 CRF01-AE subtype patients with failure of first-line antiretroviral therapy were selected, and blood samples were longitudinally collected during the course of 6 to 8 years of treatment. Genotypic analysis of drug resistance mutations was performed by high throughput sequencing.
Results ① All the patients had the M184V mutation and a certain type of non-nucleoside reverse transcriptase inhibitors (NNRTIs) high-frequency major drug resistance mutations at early stage after medication, common sites were K101E, G190A and K103N, and combination of M184V plus G190A plus TAMs was the common mutations. Mutations was still existed after stopping the corresponding drugs or switching to second-line drugs. ② In the process of thymidine analogue mutations (TAMs) formation, 3 patients had TAM2 pathway, 1 patient had TAM1 pathway, and another patient had only TAM2 pathway mutations in the early stage and accumulated TAM1 pathway mutations in the later stage. ③ Three patients formed multi-drug resistance mutations including TAMs, Q151 complex and 69 insertion complexes, and they still failed in treatment after changing the second-line regimen.
Conclusion ① CRF01-AE subtype drug resistance patients begin to develop drug resistance mutations at the early stage of drug use, and several mutations gradually lead to clinical drug resistance, so drug resistance mutation monitoring should be carried out as soon as possible. ② TAMs mutations are competitive in two pathways, CRF01-AE favors the TAM2 pathway. As the treatment time is prolonged, the two pathways can produce fusion. ③ It is recommended to carry out drug resistance testing before switching to the second-line protocol. If the resistance mutation against tenofovir (TDF) is found, the second-line regimen may be ineffective.

FullText(HTML)

References (15)

References

[1]	World Health Organization. HIV drug resistance report 2019[EB/OL]. (2019-07-05)[2020-10-01]. https://www.who.int/hiv/pub/drugresistance/hivdr-report-2019/en/.
[2]	YE J R, HAO M Q, XING H, et al. Transmitted HIV drug resistance among individuals with newly diagnosed HIV infection: a multicenter observational study[J]. AIDS, 2020, 34(4): 609-619. doi: 10.1097/QAD.0000000000002468
[3]	吴亚松, 马烨. 中国艾滋病病毒耐药现状[J]. 新发传染病电子杂志, 2019, 4(3): 181-184. doi: 10.3877/j.issn.2096-2738.2019.03.013
[4]	GUPTA R K, GREGSON J, PARKIN N, et al. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis[J]. Lancet Infect Dis, 2018, 18(3): 346-355. doi: 10.1016/S1473-3099(17)30702-8
[5]	BENNETT D E, MYATT M, BERTAGNOLIO S, et al. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment[J]. Antivir Ther, 2008, 13(Suppl 2): 25-36. http://www.paho.org/hq/dmdocuments/2009/threshold%20survey%20english.pdf
[6]	DUDLEY D M, CHIN E N, BIMBER B N, et al. Low-cost ultra-wide genotyping using Roche/454 pyrosequencing for surveillance of HIV drug resistance[J]. PLoS One, 2012, 7(5): e36494. doi: 10.1371/journal.pone.0036494
[7]	BRUN-VÉZINET F, COSTAGLIOLA D, KHALED M A, et al. Clinically validated genotype analysis: guiding principles and statistical concerns[J]. Antivir Ther, 2004, 9(4): 465-478. http://europepmc.org/abstract/MED/15456077
[8]	HIRSCH M S, GVNTHARD H F, SCHAPIRO J M, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel[J]. Clin Infect Dis, 2008, 47(2): 266-285. doi: 10.1086/589297
[9]	焦丽燕, 刘永健, 郭东星, 等. 两种HIV-1耐药准种分析方法的比较[J]. 军事医学科学院院刊, 2010, 34(3): 261-264. doi: 10.3969/j.issn.1674-9960.2010.03.017
[10]	RHEE S Y, KASSAYE S G, BARROW G, et al. HIV-1 transmitted drug resistance surveillance: shifting trends in study design and prevalence estimates[J]. J Int AIDS Soc, 2020, 23(9): e25611. doi: 10.1002/jia2.25611
[11]	FERREIRA A C G, COELHO L E, GRINSZTEJN E, et al. Transmitted drug resistance in patients with acute/recent HIV infection in Brazil[J]. Braz J Infect Dis, 2017, 21(4): 396-401. doi: 10.1016/j.bjid.2017.03.013
[12]	HASSAN A S, ESBJÖRNSSON J, WAHOME E, et al. HIV-1 subtype diversity, transmission networks and transmitted drug resistance amongst acute and early infected MSM populations from Coastal Kenya[J]. PLoS One, 2018, 13(12): e0206177. doi: 10.1371/journal.pone.0206177
[13]	WENSING A M, CALVEZ V, GVNTHARD H F, et al. 2017 update of the drug resistance mutations in HIV-1[J]. Top Antivir Med, 2016, 24(4): 132-133. http://www.researchgate.net/profile/Huldrych_Guenthard/publication/236225524_Update_of_the_Drug_Resistance_Mutations_in_HIV-1_March_2013/links/02e7e52430976e3931000000/Update-of-the-Drug-Resistance-Mutations-in-HIV-1-March-2013.pdf
[14]	阮尉月清, 刘家法, 张米, 等. 云南省男男性行为人群HIV/AIDS病例抗病毒治疗失败基因型耐药分析[J]. 预防医学, 2020, 32(10): 987-991, 995. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYFX202010006.htm
[15]	赵砚, 吕娅妮, 康续, 等. 239例治疗失败的HIV感染者HIV-1亚型及耐药分析[J]. 中国艾滋病性病, 2020, 26(10): 1045-1048. https://www.cnki.com.cn/Article/CJFDTOTAL-XBYA202010005.htm

Cited By

Cited by

Periodical cited type(3)

1.	莫金荣，周巧玉，廖炯，连晓明. 艾考恩丙替片对初治艾滋病患者的疗效及安全性评价. 实用临床医药杂志. 2024(12): 100-106 . 本站查看
2.	李小琼，王雅，董琳婕，张一帆，罗瑶. 人类免疫缺陷病毒抗体初筛阳性确证结果分析及化学发光法检测抗体吸光度值/临界值灰区范围的合理性探究. 实用临床医药杂志. 2024(21): 48-52 . 本站查看
3.	马春花，司冰倩，吴玉灵，李宗倍，裴建新，吴忠兰. HIV感染者或AIDS患者抗病毒治疗后耐药位点动态变化情况. 宁夏医科大学学报. 2023(12): 1253-1258 .

Other cited types(0)

Get Citation

PDF

XML

Article views (305) PDF downloads (20) Cited by(3)

Turn off MathJax

Article Contents

Abstract

References

Study on molecular evolutionary rules of drug resistance mutations in CRF01-AE subtype of HIV-1 strain by high-throughput sequencing

Abstract

References

Cited by

Periodical cited type(3)

Other cited types(0)

Catalog

Export File

Citation

Format

Content